Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer's.
Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.
New research suggests that inhaled xenon gas can help protect the brains of those with Alzheimer's disease.
Scientists at the West Virginia University Rockefeller Neuroscience Institute hope to unlock the true potential of drugs designed to target Alzheimer's.
Scientists have uncovered a link between having shingles and cognitive decline.
UK scientists have found evidence that liraglutide can reduce brain shrinkage and cognitive decline in Alzheimer's patients.
The test, with an accuracy rate of around 90%, could enable earlier treatment for patients with the disease.
New research finds that people given the Shingrix vaccine were significantly less likely to develop dementia over a six-year-period.
New research finds that 9/11 responders exposed to high levels of dust are more likely to suffer early dementia than those with low exposure or who wore masks.
Recent research indicates that people with two copies of the APOE4 gene are almost certain to exhibit signs of the neurological disease by their mid-60s.
While such a risk has yet to be confirmed in humans and is likely to be low, the authors urge more research into the possibility.
New research estimates that nearly half of people globally are living with a condition like Alzheimer’s, stroke, or epilepsy.
The FDA approved Biogen's $56,000 anti-amyloid drug in 2021, against the advice of outside experts.
Two studies suggest up to 10 million Americans don't know they're living with mild cognitive impairment, and few doctors identify it as often as they should.
Scientists have found evidence in mice and human brain tissue that the drug ponesimod can reduce inflammation and toxic amyloid plaques common in Alzheimer's.
The vaccine not only reduced brain inflammation in mice with Alzheimer-like illness, but improved their behavior for the better, the authors say.
The FDA's decision will allow the drug known as Leqembi to be widely available and covered through Medicare.
Eli Lilly's drug donanemab appeared to slow down the rate of cognitive decline in patients by 35% compared to placebo.
Lecanemab appeared to slow down cognitive decline in people with early Alzheimer's, though some experts question its real-world benefits.
An investigative report suggests that lecanemab can raise the risk of severe brain bleeding when taken with a blood thinner.
Mode
Follow us
